X0202 4 2005-09-30 1 0000929547 INKINE PHARMACEUTICAL CO INC INKP 0001316741 Cullen John 1787 SENTRY PARKWAY WEST BUILDING 18 SUITE 440 BLUE BELL PA 19422 1 Sr. VP and GC Copmmon Stock (right to buy) 3.05 2005-09-30 4 D 0 50000 D 2015-03-01 Common Stock 50000 0 D All of the options described above were converted in the merger into options to purchase Salix common stock based on an exchange ratio of 0.1737. These options, which are fully vested, now represent the right to purchase 8,685 shares of Salix common stock at a weighted average exercise price of $17.56 per share. Robert F. Apple, as attorney-in-fact for John M. Cullen, Ph.D., J.D. 2005-10-04